Regulated, long-term expression of anti-HIV antibodies via B cell receptor-targeted lentiviral transduction

Active Grant Awarded

Award ID
R01AI200582
Recipient
Awarding agency
Obligated
$5,927,367

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 4% complete
Place of performance
Los Angeles, CA 90095, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases awarded University of California, Los Angeles, acting through its Office of Research Administration, a grant totaling $5.927367 million on September 23, 2026, under Assistance Listing 93.855, Allergy and Infectious Diseases Research. The grant funds the project "Regulated, Long-Term Expression of Anti-HIV Antibodies via B Cell Receptor-Targeted Lentiviral Transduction." The recipient has developed lentiviral vectors that selectively transduce splenic B cells, and the project uses that system to express anti-HIV-1 proteins in B cells. The work will express ECD4-Ig, a highly potent anti-HIV-1 reagent consisting of IgG and soluble CD4, and leronlimab, an antibody against the HIV-1 co-receptor CCR5, in immunocompetent mice. The project will investigate whether B-cell-specific expression produces long-term anti-HIV-1 antibodies without inducing immune reactions to those antibodies. The period of performance ends August 31, 2030. Place of performance is Los Angeles, CA 90095.

Description

Abstract
Neutralizing antibodies against HIV-1 are very potent in suppressing HIV-1 replication. However, the serum concentrations of the antibodies must be kept at therapeutic levels for long periods of time to eliminate HIV-1-infected cells, because persistently infected cells reside in the deep tissue. Therefore, multiple administrations of the antibodies are required, which could be expensive and labor-intensive. Gene therapy vectors can be used to produce therapeutic antibodies. However, transgene expression by any gene therapy vectors, including lentiviral vectors, can induce immune reactions against the transgenes, thereby decreasing the therapeutic effects of transgene products and eliminating the transduced cells. Therefore, IT is important to express transgenes in the cell types that can develop tolerance to transgene products. B-cells physiologically express wide varieties of valuable antibody regions generated by recombination and mutations in genes. B-cells are known to induce tolerance to the valuable regions. This ability of B-cells was previously used to induce tolerance to self-antigens for therapy of autoimmune diseases and coagulation factor IX for treatment of hemophilia. Therefore, transduction of B-cells is likely to generate long-term anti-HIV-1 antibodies without inducing immune reactions to the antibodies. We have developed lentiviral vectors that can selectively transduces splenic B-cells. By exploiting this B-cell-specific transduction by our lentiviral vectors, we will attempt to express anti-HIV-1 proteins specifically in B-cells. Using this B-cell-specific transgene expression system, we will express ECD4-IG, a highly potent anti-HIV-1 reagent consisting of IGG and soluble CD4, and leronlimab, an antibody against HIV-1 CO-receptor CCR5, in immunocompetent mice. We will investigate whether expression, specifically in B-cells, can induce long-term expression of ECD4-IG and leronlimab. We will next induce BCR signaling of transduced B-cells to induce their proliferation and differentiation. The growth of transduced B-cells will increase the serum concentrations of the antibodies. Differentiation of transduced cells to memory B-cells and plasma cells will extend the period of ECD4-IG and leronlimab expression by prolonging the life span of transduced B-cells. We will then evaluate the therapeutic effects of B-cell-specific expression of the antibodies in HIV-1 infection of humanized mice. We will also attempt to express anti-HIV-1 BCR on transduced cells, which will induce growth, differentiation, and relocation of transduced B cells in response to their exposure to HIV-1 envelope proteins. These experiments are designed to develop a novel gene therapeutic antibody therapy that can be applied not only to therapy of HIV-1 infection, but also other types of infectious diseases.

Quick answers

Who received award R01AI200582?

R01AI200582 was awarded to University Of California, LOS Angeles by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 23, 2026.

How much is award R01AI200582 worth?

$5,927,367 has been obligated on R01AI200582.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award